Asia-Pacific Intravenous Immunoglobulin Market

The APAC intravenous immunoglobulin market is expected to grow from US$ 2,609.61 million in 2022 to US$ 4,156.85 million by 2028. It is estimated to grow at a CAGR of 8.1% from 2022 to 2028.

Strong Pipeline Candidates for IVIG

Leading players in the intravenous immunoglobulin market have multiple projects, and many biological products in pipelines are based on proprietary technology. For instance, Evolve Biologics aims to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. The company is developing a portfolio of product candidates, IVIG, which completed its Phase III clinical trial in February 2021. Similarly, Biotest is a global company that offers plasma protein products and biotherapeutic drugs. The company is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases. In September 2020, the company completed its phase III trial investigating IgG Next Generation for patients with primary immunodeficiency disease (PID). Thus, strong pipeline candidates for IVIG are expected to become a trend in the intravenous immunoglobulin market.

Market Overview

Asia Pacific (APAC) is the fastest-growing regional market for intravenous immunoglobulin. China, India, Japan, South Korea, Australia, and the Rest of APAC are the major contributors to the market in this region. Asia Pacific is likely to account for over 21.68% market share of the global intravenous immunoglobulin market in 2022 due to the increasing geriatric population, the rising prevalence of immune deficiency disorders, and the increasing adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Therefore, the region holds huge potential for the intravenous immunoglobulin market players to grow during the forecast period. China is a developing country in Asia Pacific with a well-established healthcare system and a fast-growing pharmaceutical industry. China is home to various medical, pharmaceutical, and biotechnology product manufacturing companies operating in the global market. China also has over 300 medical contract research organizations, along with prominent biopharmaceutical product manufacturers—including China Biologic Products Holdings, Inc. and Shanghai RAAS. These pharmaceutical companies are prone to global market competition, which encourages them to introduce innovative products, thereby boosting the growth of the intravenous immunoglobulin market.

 APAC Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

Asia-Pacific Intravenous Immunoglobulin Strategic Insights

Strategic insights for the Asia-Pacific Intravenous Immunoglobulin provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia-Pacific Intravenous Immunoglobulin Report Scope

Asia-Pacific Intravenous Immunoglobulin Regional Insights

The geographic scope of the Asia-Pacific Intravenous Immunoglobulin refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

APAC Intravenous Immunoglobulin Market Segmentation

The APAC intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

• Based on application, the APAC intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
• Based on distribution channel, the APAC intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
• Based on end user, the APAC intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
• Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China dominated the market in 2022.

ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.